MedTrace Logo

Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

NCT07014917 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2026-01-06

No results posted yet for this study

Summary

This is a randomized Phase II study of intermittent versus continuous venetoclax therapy with Acalabrutinib in previously untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Conditions

Interventions

DRUG

Venetoclax

intermittent venetoclax (7days administration per cycle) + acalabrutinib

DRUG

Acalabrutinib

intermittent venetoclax (7days administration per cycle) + acalabrutinib

DRUG

Venetoclax

continuous venetoclax (28 days administrations per cycle) + acalabrutinib

DRUG

Acalabrutinib

continuous venetoclax (28 days administrations per cycle) + acalabrutinib

Sponsors & Collaborators

  • Zulfa Omer

    lead OTHER

Principal Investigators

  • Zulfa Omer · University of Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-05
Primary Completion
2028-06-05
Completion
2032-06-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07014917 on ClinicalTrials.gov